Ikena Oncology, Inc. (IKNA)

Market Cap	74.80M
Revenue (ttm)	659,000
Net Income (ttm)	-59.60M
Shares Out	48.26M
EPS (ttm)	-1.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,946
Open	1.620
Previous Close	1.610
Day's Range	1.550 - 1.620
52-Week Range	1.220 - 2.300
Beta	0.49
Analysts	Buy
Price Target	3.00 (+93.55%)
Earnings Date	Nov 7, 2024

About IKNA

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 26, 2021
• Employees: 43
• Stock Exchange: NASDAQ
• Ticker Symbol: IKNA
• Website: https://ikenaoncology.com

Financial Performance

In 2023, Ikena Oncology's revenue was $9.16 million, a decrease of -41.35% compared to the previous year's $15.62 million. Losses were -$68.17 million, -0.87% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for IKNA stock is "Buy." The 12-month stock price forecast is $3.0, which is an increase of 93.55% from the latest price.

Price Target

$3.0

(93.55% upside)

Analyst Consensus: Buy